BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28728859)

  • 21. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
    Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
    Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
    Binder G
    Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. After 95 years, it's time to eRASe JMML.
    Meynier S; Rieux-Laucat F
    Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
    Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
    J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
    Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
    Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia.
    Yoshimi A; Kamachi Y; Imai K; Watanabe N; Nakadate H; Kanazawa T; Ozono S; Kobayashi R; Yoshida M; Kobayashi C; Hama A; Muramatsu H; Sasahara Y; Jakob M; Morio T; Ehl S; Manabe A; Niemeyer C; Kojima S
    Pediatr Blood Cancer; 2013 May; 60(5):836-41. PubMed ID: 23023736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
    Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
    BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report.
    Ortiz MV; Skoda-Smith S; Rauen KA; Allan RW; Slayton WB
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):569-72. PubMed ID: 22510777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsyndromic Juvenile Myelomonocytic Leukemia With PTPN11 Mutation in a 9-Year-old Girl.
    Sarper N; Gelen SA; Zengin E; Demirsoy U; Erçin C
    J Pediatr Hematol Oncol; 2015 Aug; 37(6):486-7. PubMed ID: 26181421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
    Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
    Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Congenital Chylothorax as the Initial Presentation of PTPN11-Associated Noonan Syndrome.
    Ebrahimi-Fakhari D; Freiman E; Wojcik MH; Krone K; Casey A; Winn AS; Roberts AE; Harper BD
    J Pediatr; 2017 Jun; 185():248-248.e1. PubMed ID: 28363362
    [No Abstract]   [Full Text] [Related]  

  • 38. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
    Lee ST; Ki CS; Lee HJ
    Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
    Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
    Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.